I am interested in collaborations
Semaglutide mimics the activity of a hormone naturally produced by humans in their intestines known as glucagon-like peptide 1 or, popularly, GLP-1. The release of this hormone in the body and consequent activation of GLP-1 receptors increases insulin release, causing a reduction in blood glucose levels, an important role in the treatment of diabetes.
This is a recent promise to handle obesity, and Science recognized as a big achievement on the fight against obesity.
During my PhD, I have created and worked with models focused on GLP-1, and on the guts.
#bioinformatics #biomathematics #obesity
In fact, I have thought similar. My PhD was in ghrelin. In the past, they have also used ghrelin, until, they found its relation with heart attack. It is possible that it is just a matte of time to someone prove that GPL-1 has bad side effects, in addition to what they already know.
Making models and more could be a path to better understand and criticize this option against obesity.
Please check repeatedly the pancreatic enzymes amylase and lipase of your patients during treatment: you'll have a nasty surprise.
- Badges
- Science method
- Similar topics
- Teaching